Glepaglutide, a long-acting glucagon-like peptide-2 analog, alters postprandial intestinal hormone levels but not glucose homeostasis in patients with short bowel syndrome. (September 2018) - Naimi, R.M.; Hvistendahl, M.; Holst, J.J.; Hartmann, B.; Hansen, M.B.; Jeppesen, P.B.